New Delhi: Panacea Biotec has announced that the company has received an Award notification from Pan American Health Organization, Regional Office of World Health Organization (PAHO) under a Long- Term Agreement for supply of Diphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus influenzae type B (DTP-HepB-Hib) Vaccine (Pentavalent) - Liquid (single dose) (“Easyfive-TT”) to PAHO, valid until December 31, 2027. The total award to the Company for supply of Vaccine amounts to Rs 41 crore during Calendar Year 2026 and 2027. Read also: Panacea Biotec, Apotex resolve dispute over breach of collaboration agreement Panacea Biotec is a Biotechnology company doing Research and Development, Manufacturing, Sales, Distribution and Marketing of Pharmaceuticals and Vaccines. Panacea Bi

See Full Page